Subsequently, a clinical trial performed [106] through intravenous administration of TAK-101 nanoparticles in CeD patients on a GFD underwent to gluten challenge, showed that Ag-specific T cell response induced by the gluten challenge was reduced compared to a placebo group, indicating that TAK-101 acts in an Ag-specific manner. This evidence concerns the gene RENBP and cranioectodermal dysplasia.